An observational study in To Evaluate Lower Urinary Tract Symptoms (LUTS) in Poland, sponsored by Jagiellonian University. Completed at 1 site in Poland. Open to participants aged 40 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-06.
Sponsored by Jagiellonian University · Observational
The first large population-based study to evaluate lower urinary tract symptoms (LUTS) in Poland. The study objective is to assess the prevalence and bother of LUTS in the population aged ≥40 years in Poland.
The first large population-based study to evaluate lower urinary tract symptoms (LUTS) in Poland. The study objective is to assess the prevalence and bother of LUTS in the population aged ≥40 years in Poland.
This study will be conducted as a telephone survey with assessment of LUTS using a standardized protocol, which included the International Prostate Symptom Score (IPSS) and, for overactive bladder (OAB), the OAB-V8 questionnaire. Participants will be asked to rate how often they experienced individual LUTS and the degree of associated bother.
The study will be performed in a representative group of Polish population (n = 6,000) covering all geographic regions of Poland (defined by the Central Statistical Office of Poland).
406 studies on the registry are indexed under Lower Urinary Tract Symptoms; 110 are open to participants now.
This study's enrollment of 6,000 is above the median of 179 across 132 observational studies indexed under Lower Urinary Tract Symptoms.
Browse Lower Urinary Tract Symptoms studies →Jagiellonian University is the lead sponsor of 156 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Representative group of Polish population
Age >40
Exclusion Criteria:
Age \<40 Pregnancy Urinary tract infection in the past 4 weeks
There will be no intervention
Prevalence of LUTS
The prevalence of LUTS will be assessed using definitions of the International Continence Society (descriptive statistics).
Time frame: Through study completion, an average of 3 months
Symptom bother of LUTS
The degree of associated bother will be assessed using Likert scale (Likert scale: not at all \[score 0\], a little bit \[score 1\], somewhat \[score 2\], quite a bit \[score 3\], a great deal \[score 4\], or a very great deal \[score 5\]).
Time frame: Through study completion, an average of 3 months
Prevalence of specific symptoms
The prevalence of specific symptoms will be assessed using a standardised protocol based on the definitions provided by the International Continence Society (i.e. storage symptoms, voiding symptoms and post-micturition symptoms) \[Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167-178\]. Participants will be asked to rate how often they experienced individual LUTS during the past month. A Likert scale will be used with the following options: none (score 0), \<1 in 5 times (score 1), \<half the time (score 2), about half the time (score 3), \>half the time (score 4), or almost always (score 5).
Time frame: Through study completion, an average of 3 months
Symptom bother of specific symptoms
The degree of associated bother of specific symptoms will be assessed using Likert scale (Likert scale: not at all \[score 0\], a little bit \[score 1\], somewhat \[score 2\], quite a bit \[score 3\], a great deal \[score 4\], or a very great deal \[score 5\]).
Time frame: Through study completion, an average of 3 months
Prevalence of OAB
The prevalence of OAB will be assessed with the Overactive Bladder-Validated 8-question Screener (OAB-V8)questionnaire.
Time frame: Through study completion, an average of 3 months
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jagiellonian University